Crohn's drug trial halted early: what happened?

NCT ID NCT03961815

Terminated Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to see if brazikumab is safe and tolerable over the long term for people with moderate to severe Crohn's disease. It enrolled 18 participants who had previously been in a related study. The trial was terminated early, meaning it did not reach its planned end, so the results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brazikumab
What this could lead to: If successful, this could provide a long-term treatment option for people with moderate to severe Crohn's disease.
What could go wrong: The study was terminated early and included only 18 participants, so it is too small to draw firm conclusions. The drug may not work or may have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN'S DISEASE IBD

Contacts and locations

Locations

Research Site

Lincoln, California, 95648, United States
Research Site

Clearwater, Florida, 33756, United States
Research Site

Kissimmee, Florida, 34741, United States
Research Site

Lakeland, Florida, 33813, United States
Research Site

Miami, Florida, 33157, United States
Research Site

Miami, Florida, 33165, United States
Research Site

Miami Lakes, Florida, 33016, United States
Research Site

Tampa, Florida, 33626, United States
Research Site

Beachwood, Ohio, 44122, United States
Research Site

Houston, Texas, 77058, United States
Research Site

Hamburg, 20251, Germany
Research Site

Rzeszów, 35-302, Poland
Research Site

Cape Town, 7500, South Africa
Research Site

Plumstead, 7800, South Africa
Research Site

Taichung, 40443, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.